Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Danube Pharmaceuticals Inc.

www.danubepharma.com

Latest From Danube Pharmaceuticals Inc.

The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind.

BioPharmaceutical Deals

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology

The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
BioPharmaceutical Strategy

Danube Pharmaceuticals Inc.

Biotech start-up Danube Pharmaceuticals Inc. has in-licensed what it calls the only dual-mechanism of action, orally available small molecule in clinical testing for glaucoma, a leading cause of irreversible blindness worldwide.
BioPharmaceutical Strategy

Start-Up Previews (7/06)

A preview of the emerging health care companies profiled in the current, all profiles issue of Start-Up. This month's profile groups: Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology, Neurostimulation's Billion Dollar Markets, and Antibacterial Drug Development. Plus these Start-Up Across Health Care: Ascenta Therapeutics, CircuLite, CoroNovative and Endovalve.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Danube Pharmaceuticals Inc.
  • Senior Management
  • Barrett Katz, MD, CEO
    Dave Tanen, Pres.
  • Contact Info
  • Danube Pharmaceuticals Inc.
    Phone: (212) 871-7900
    689 5th Avenue
    12th Fl.
    New York, NY 10022
    USA
UsernamePublicRestriction

Register